HK Innoen Introduces Biosimilar of Targeted Bone Disease Treatment 'Denosumab'

Exclusive Supply of Two Biosimilars
Targeting Domestic Approval in 2025

Panorama of HK Inno.N Osong Plant＜Photo by HK Inno.N＞

[Asia Economy Reporter Myung-hwan Lee] HK inno.N announced on the 25th that it has signed an exclusive domestic license agreement with Spain's Mapscience for denosumab biosimilars, preventive treatments for osteoporosis and cancer-related skeletal complications.

Under this agreement, HK inno.N will receive exclusive supply of two denosumab biosimilars from Mapscience and will proceed with domestic approval applications and sales.

By securing domestic rights to the denosumab biosimilars, HK inno.N will be able to quickly enter the market. According to HK inno.N, the denosumab market has shown an average annual sales growth rate of over 70% in the past five years.

Denosumab is an antibody therapeutic that targets the ‘RANKL’ protein, which is essential for the survival and function of osteoclasts, exhibiting a strong inhibitory effect on bone resorption. The original products are Amgen’s osteoporosis treatment 'Prolia' and 'Xgeva,' used for preventing skeletal complications in cancer patients with bone metastases and treating giant cell tumor of bone. According to IQVIA data, these products recorded sales of approximately 120 billion KRW from October 2021 to September last year. Their patents are set to expire in 2025.

HK inno.N plans to swiftly pursue domestic approval for these denosumab biosimilars to secure new growth engines. Kwak Dal-won, CEO of HK inno.N, stated, "The denosumab market continues to grow steadily due to its excellent efficacy and convenience," adding, "Through the introduction of biosimilars, we will provide new treatment options for osteoporosis patients and cancer patients suffering from skeletal complications."

Meanwhile, Mapscience is a Spain-based company specializing in the development, production, and commercialization of biopharmaceuticals, and was acquired last year by Germany’s Fresenius Kabi. Mapscience is currently conducting clinical trials to confirm clinical equivalence with the original denosumab products.

This content was produced with the assistance of AI translation services.